Arne Simon1, Susanne Gehrmann2, Gudrun Wagenpfeil3, Stefan Wagenpfeil3. 1. Department of Pediatric Oncology and Hematology, Children's Hospital Medical Center, University Hospital of Saarland, Homburg, Germany. Arne.Simon@uks.eu. 2. Medical Unit Leader, Medical Affairs Department, AbbVie Deutschland GmbH & Co.KG, Wiesbaden, Germany. 3. Institutes for Medical Biometry, Epidemiology and Medical Informatics (IMBEI), Campus Homburg, Saarland University, Homburg, Germany.
Abstract
Infants with Down syndrome (DS) face an increased risk of respiratory tract infections. Recent studies describe DS as independent risk factor for a complicated clinical course in infants with respiratory syncytial virus (RSV) infection. The prospective observational German Synagis™ Registry comprises data from 249 children below 25 months of age with DS and palivizumab prophylaxis 2009-2016 (1191 administrations; mean 4.8 per patient and season). The median gestational age and the birth weight in patients without and with DS were 31 versus 37 weeks (P < 0.001) and 1590 versus 2750 g, respectively (P < 0.001). Patients with DS significantly more often had congenital heart disease (CHD), siblings in kindergarten or school, treatment with oxygen at home, immunodeficiency, and neuromuscular impairment. The RSV-related hospitalization rate in patients with DS was 1.20%; the hospitalization rate in patients without DS was 0.71%. CONCLUSION: Data from 249 children with DS receiving palivizumab prophylaxis in seven consecutive RSV seasons (2009-2016) in Germany reveal important differences between patients with and without DS concerning the main indication for palivizumab use and additional risk factors. Bearing in mind the limitations of an uncontrolled postmarketing observational study, the results confirm the field effectiveness of palivizumab prophylaxis in this special population. What is Known: • Recent studies describe the Down syndrome as independent risk factor for a complicated clinical course in infants with RSV infection. What is New: • Compared with other infants receiving palivizumab prophylaxis, patients with Down syndrome significantly more often had congenital heart disease, siblings in kindergarten or school, treatment with oxygen at home, immunodeficiency, and neuromuscular impairment. • In infants with palivizumab prophylaxis breakthrough, RSV-related hospitalization rates were not significantly higher in those with Down syndrome.
Infants with Down syndrome (DS) face an increased risk of respiratory tract infections. Recent studies describe DS as independent risk factor for a complicated clinical course in infants with respiratory syncytial virus (RSV) infection. The prospective observational German Synagis™ Registry comprises data from 249 children below 25 months of age with DS and palivizumab prophylaxis 2009-2016 (1191 administrations; mean 4.8 per patient and season). The median gestational age and the birth weight in patients without and with DS were 31 versus 37 weeks (P < 0.001) and 1590 versus 2750 g, respectively (P < 0.001). Patients with DS significantly more often had congenital heart disease (CHD), siblings in kindergarten or school, treatment with oxygen at home, immunodeficiency, and neuromuscular impairment. The RSV-related hospitalization rate in patients with DS was 1.20%; the hospitalization rate in patients without DS was 0.71%. CONCLUSION: Data from 249 children with DS receiving palivizumab prophylaxis in seven consecutive RSV seasons (2009-2016) in Germany reveal important differences between patients with and without DS concerning the main indication for palivizumab use and additional risk factors. Bearing in mind the limitations of an uncontrolled postmarketing observational study, the results confirm the field effectiveness of palivizumab prophylaxis in this special population. What is Known: • Recent studies describe the Down syndrome as independent risk factor for a complicated clinical course in infants with RSV infection. What is New: • Compared with other infants receiving palivizumab prophylaxis, patients with Down syndrome significantly more often had congenital heart disease, siblings in kindergarten or school, treatment with oxygen at home, immunodeficiency, and neuromuscular impairment. • In infants with palivizumab prophylaxis breakthrough, RSV-related hospitalization rates were not significantly higher in those with Down syndrome.
Authors: Nansi S Boghossian; Nellie I Hansen; Edward F Bell; Barbara J Stoll; Jeffrey C Murray; Abbot R Laptook; Seetha Shankaran; Michele C Walsh; Abhik Das; Rosemary D Higgins Journal: Pediatrics Date: 2010-11-22 Impact factor: 7.124
Authors: Hao Yi; Krista L Lanctôt; Louis Bont; Beatrijs L P Bloemers; Michel Weijerman; Chantal Broers; Abby Li; Alexander Kiss; Ian Mitchell; Bosco Paes Journal: Pediatrics Date: 2014-05-05 Impact factor: 7.124
Authors: Beatrijs L P Bloemers; A Marceline van Furth; Michel E Weijerman; Reinoud J B J Gemke; Chantal J M Broers; Kimberly van den Ende; Jan L L Kimpen; Jan L M Strengers; Louis J Bont Journal: Pediatrics Date: 2007-10 Impact factor: 7.124
Authors: K Kristensen; L G Stensballe; J Bjerre; D Roth; N Fisker; T Kongstad; A L Svendsen; B W Nielsen Journal: Arch Dis Child Date: 2009-06-18 Impact factor: 3.791
Authors: Yvette N Löwensteyn; Emily W E M Phijffer; Juliette V L Simons; Nienke M Scheltema; Natalie I Mazur; Harish Nair; Louis J Bont Journal: Pediatr Infect Dis J Date: 2020-08 Impact factor: 3.806